---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-001682"
form_type: "8-K"
ticker: "DARE"
cik: "0001401914"
company_name: "Dare Bioscience, Inc."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T01:38:27.511897+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Dare Bioscience reports FY2024 cash $15.7M, plans Sildenafil Cream 503B launch in Q4 2025

## Summary
- Cash and equivalents $15.7M at Dec 31, 2024; working capital deficit of $3.2M.
- G&A expenses $9.2M (down 24% YoY); R&D expenses $14.2M (down 34% YoY).
- Plans to make proprietary Sildenafil Cream 3.6% available via 503B compounding in Q4 2025; expects revenue and cash flow from Q4.
- Ovaprene Phase 3 contraceptive study ongoing; half of 125 participants to complete ~6 months by Q2 2025 for interim DSMB review.
- DARE-LARC1 received $3.5M grant in 2024; total $31.8M of up to $49M foundation grant received to date.

## SEC filing metadata
- accession: 0001641172-25-001682
- form_type: 8-K
- ticker: DARE
- cik: 0001401914
- company_name: Dare Bioscience, Inc.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401914/000164117225001682/0001641172-25-001682-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401914/000164117225001682/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-001682
- JSON: https://secwatch.observer/filing/0001641172-25-001682.json
- Plain text: https://secwatch.observer/filing/0001641172-25-001682.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.